XELPROS Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9539262 | SUN PHARM | Ophthalmic composition comprising a prostaglandin |
Oct, 2028
(4 years from now) | |
| US9629852 | SUN PHARM | Ophthalmic composition comprising a prostaglandin |
Sep, 2029
(5 years from now) | |
Xelpros is owned by Sun Pharm.
Xelpros contains Latanoprost.
Xelpros has a total of 2 drug patents out of which 0 drug patents have expired.
Xelpros was authorised for market use on 12 September, 2018.
Xelpros is available in emulsion;ophthalmic dosage forms.
Xelpros can be used as reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The generics of Xelpros are possible to be released after 12 September, 2029.
Drugs and Companies using LATANOPROST ingredient
Market Authorisation Date: 12 September, 2018
Treatment: Reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Dosage: EMULSION;OPHTHALMIC
More Information on Dosage
XELPROS family patents
